Cytoreductive surgery for advanced stages of ovarian cancer

Seminars in Surgical Oncology

Volumn 19, Issue 1, 2000, Pages 42-48

  Dauplat, Jacques ^a   Le Bouëdec, Guillaume ^a   Pomel, Christophe ^a   Scherer, Christophe ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

Biopsy; Carcinoma; Combined antineoplastic agents; Combined modality therapy; Lymph node excision; Neoplasm staging; Ovarian neoplasms surgery drug therapy; Postoperative complications; Prognosis; Reoperation; Survival rate

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CARCINOMATOUS PERITONITIS; HUMAN; INTESTINE RESECTION; LYMPHADENECTOMY; OVARY CANCER; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURGICAL APPROACH; SURVIVAL TIME; TUMOR VOLUME;

FEASIBILITY STUDIES; FEMALE; HUMANS; LAPAROTOMY; LYMPH NODE EXCISION; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0033949464     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2388(200007/08)19:1<42::AID-SSU7>3.0.CO;2-M     Document Type: Review

References (55)

1. Griffiths CT, Fuller AF: Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Symposium on Gynecologic Cancer. Surg Clin North Am 1978;58:131-142.
2. Hacker NF, Berek JS, Lagasse LD, et al: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61: 413-420.
3. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1992;47:159-166.
4. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
5. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756-767.
6. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdomino-pelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11:166-172.
7. Meyer JI, Kennedy AW, Friedman R, et al: Ovarian carcinoma: value of CT in predicting success of debulking sursery. AJR. Am J Roentgenol 1995;165:875-878.
8. Hudson CN: A radical operation for fixed ovarian tumours. J Obstet Gynaec Br Commonw 1968;75:1155-1160.
9. Eisenkop SM, Nalick RH, Teng NN: Modified posterior exenteration for ovarian cancer. Obstet Gynecol 1991;78(5 Pt 1):879-885.
10. Barnes W, Johnson J, Waggoner S, et al: Reverse hysterocolposigmoidectomy (RHCS) for resection of panpelvic tumors. Gynecol Oncol 1991;42:151-155.
11. Knight CD, Griffen FD: An improved technique for low anterior resection of the rectum using the EEA stapler. Surgery 1980; 88:710-714.
12. Nicklin JL, Copeland LJ, O'Toole RV, et al: Splenectomy as part of cytoreductive surgery for ovarian carcinoma [Review]. Gynecol Oncol 1995;58:244-247.
13. Adelson MD, Baggish MS, Seifer DB, et al: Cytoreduction of ovarian cancer with the Cavitron ultrasonic surgical aspirator. Obstet Gynecol 1988;72:140-143.
14. Patsner B: Carbon dioxide laser vaporization of diaphragmatic metastases for cytoreduction of ovarian epithelial cancer. Obstet Gynecol 1990;76:724-727.
15. Kapnick SJ, Griffiths CT, Finkler NJ: Occult pleural involvement in stage III ovarian carcinoma: role of diaphragm resection. Gynecol Oncol 1990;39:135-138.
16. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995; 221:29-42.
17. Kauffmann P, Le Bouëdec G, Dauplat J: Exérèses digestives dans les cancers de l'ovaire [Bowel resections in cancers of the ovary]. J Gynecol Obstet Biol Reprod 1993;22:501-508. (Fre)
18. Wu PC, Lang JH, Huang RL, et al: Intestinal metastasis and operation in ovarian cancer: a report on 62 cases [Review]. Baillieres Clin Obstet Gynaecol 1989;3:95-108.
19. Joyeux H, Szawlowski AW, Saint-Aubert B, et al: Aggressive regional surgery for advanced ovarian carcinoma. Cancer 1986; 57:142-147.
20. Chen SS, Lee L: Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. Gynecol Oncol 1983;16:95-100.
21. Wu PC, Lang JH, Huang RL, et al: Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer [Review]. Baillieres Clin Obstet Gynaecol 1989;3:143-155.
22. Burghardt E, Girardi F, Lahousen M, et al: Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991;40:103-106.
23. Tsuruchi N, Kamura T, Tsukamoto N, et al: Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer - a multivariate analysis. Gynecol Oncol 1993;49:51-55.
24. Benedetti-Panici P, Greggi S, Maneschi F, et al: Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol 1993;51:150-154.
25. Onda T, Yoshikawa H, Yokota H, et al: Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer 1996;78:803-808.
26. Dauplat J, Hacker NF, Nieberg RK, et al: Distant metastases in epithelial ovarian carcinoma. Cancer 1987;60:1561-1566.
27. Burghardt E, Winter R: The effect of chemotherapy on lymph node metastases in ovarian cancer [Review]. Baillieres Clin Obstet Gynecol 1989;3:167-171.
28. Podratz KC, Malkasian GD Jr, Wieand HS, et al: Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988;29:274-282.
29. Kigawa J, Minagawa Y, Itamochi H, et al: Retroperitoneal lymphadenectomy, including the para-aortic nodes in patients with stage III ovarian cancer. Am J Clin Oncol 1994;17:230-233.
30. Spirtos NM, Gross GM, Freddo JL, Ballon SC: Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 1995; 56:345-352.
31. Scarabelli C, Gallo A, Zarrelli A, et al: Sytematic pelvic and paraaortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival [published erratum appears in Gynecol Oncol 1995;58:417]. Gynecol Oncol 1995;56:328-337.
32. Scarabelli C, Gallo A, Visentin MC, et al: Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer 1997;7:18-26.
33. Beneditti Panici P, Landoni F, Scarabelli C, et al: Systematic aortic and pelvic lymphadenectomy (SAPL) vs resection of any bulky nodes (RBN) only for optimally debulked advanced ovarian cancer (AOC): preliminary report from an international randomized trial [Abstract]. Seventh Biennial Meeting of the International Gynecologic Cancer Society; 1999 Sept 26-30; Rome, Italy: Int J Gynecol Cancer 1999;9(Suppl 1):44, #A132.
34. Le Bouëdec G, Ben Ahmed S, Plagne R, Dauplat J: Cancers épithéliaux de l'ovaire de stades III et IV. Rôle pronostique de la réduction tumorale chirurgicale [Stage III and IV epithelial cancer of the ovary. Prognostic role of surgical tumor reduction]. Presse Méd 1990;19:506-510. (Fre)
35. Bertelsen K: Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990; 38:203-209.
36. Heintz AP, Hacker NF, Berek JS, et al: Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986; 67:783-788.
37. Chen SS, Bochner R: Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol 1985;20:190-195.
38. Eisenkop SM, Spirtos NM, Montag TW, et al: The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-209.
39. Michel G, De Iaco P, Castaigne D, et al: Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaec Oncol 1997; 18:9-15.
40. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5:1157-1168.
41. Del Campo JM, Felip E, Rubio D, et al: Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 1994;53:27-32.
42. Venesmaa P: Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990. Obstet Gynecol 1994; 84:8-11.
43. Petit T, Dufour P, Barrats JC, et al: Carboplatine et cyclophosphamide dans les cancers de l'ovaire de stade Ic à IV: une série de 101 patients [Carboplatin and cyclophosphamide in stage Ic-IV ovarian carcinoma: retrospective study of 10 cases] [Review]. Bull Cancer 1996;83:566-572. (Fre)
44. Piver MS, Lele SB, Marchetti DL, et al: The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988;6:983-989.
45. Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103-108.
46. Hunter RW, Alexander ND, Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery and independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-511.
47. Goodman HM, Harlow BL, Sheets EE, et al: The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 1992;46:367-371.
48. rd, Morris M, et al: Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-17.
49. Curtin JP, Malik R, Venkatraman ES, et al: Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9-12.
50. Liu PC, Benjamin I, Morgan MA, et al: Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997;64:4-8.
51. Bristow RE, Montz FJ, Lagasse LD, et al: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278-287.
52. Potter ME, Partridge EE, Hatch KD, et al: Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991; 40:195-200.
53. LoCoco S, Covens A, Carney M, et al: Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol 1995; 59:194-199.
54. Hacker NF: Cytoreduction for advanced ovarian cancer in perspective. Int J Gynecol Cancer 1996;6:159-160.
55. van der Burg ME, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332: 629-634.